May 2025
FDA Delays Continue as Regulator Misses Review Date for GSKs Nucala
United States Food and Drug Administration, Nucala, Chronic Obstructive Airway Disease, GSK ‘s, Target, delays, PDUFA
FDA eyes full AI integration by June as Makary touts genAI pilot success
United States Food and Drug Administration, Aortic Valve Insufficiency, DNA Integration, Artificial Intelligence, Makary, June
Lilly backs $65M raise for biotech plumbing the ‘dark genome’ with AI
Haya, Eli Lilly, Genome, Long Intergenic Non-Protein Coding RNA, Obesity, Aortic Valve Insufficiency, Eli, Dark color
Citing tariffs, Illumina slashes guidance, confirms SEC’s Grail investigation is closed
Illumina, SEC, Acquisition (action), Evaluation, divestiture, Grail
Pivotal readouts on deck as Takeda sees stagnant sales this year
Takeda, Phase 3, Pivotal, Growth, Sales – occupational activity, JPY
Blood cancer biotech Vor Bio ends clinical work, lays off 95% of staff
Hematologic Neoplasms, Leukemia, Myelocytic, Acute, Reflex, Vestibulo-Ocular, gene therapy, 95%
AI Drug Discovery Firm Insitro Lays Off 22% of Workforce Amid Ongoing Biotech Market Turmoil
Insitro, AI drug discovery, biotechnology layoffs, workforce reduction, tumultuous market, industry restructuring, biotech market trends, clinic readiness, cost-cutting, 2025 biotech layoffs
Takeda announces handful of pipeline cuts in effort to pivot resources
Takeda, pipeline, restructuring, Solid Neoplasm, pivot resources
Gilead tees up $11B in new US manufacturing, R&D investments
United States, Investments, Manufacture, R&D, Billion, U.S.
In first oncology expert meeting under Makary, FDA spotlights cancer drugs from J&J, Pfizer, Roche and UroGen
United States Food and Drug Administration, oncology expert, J&J, Pfizer, Roche (company), UroGen